Elsevier,

Diagnosis and Management in Dementia, Volume 1, August 2020, Pages 665-680

This book chapter advances SDGs 3 and 17 by describing how acute hospital settings can affect the care of patients with dementia. As well as changes to the physical hospital environment, this requires an enhanced focus on key strategies such as reliable identification of cognitive impairment, access to comprehensive geriatric assessment, prevention and management of delirium, and timely discharge planning are included in the chapter.
This book chapter advances SDGs 3 and 17 by reviewing pathological and functional outcomes of both preventative and therapeutic environmental enrichment on commonly used mouse models of amyloid pathology.
Elsevier,

Diagnosis and Management in Dementia, Volume 1, August 2020, Pages 827-842

This book chapter advances SDGs 3 and 17 by discussing the potential impact of dementia on creativity, physical activity, and exercise participation and whether exercise and creativity may each exert individual effects on the maintenance and/or facilitation of cognitive health. This chapter explores the context of biological and theoretical mechanisms underlying dementia and provide recommendations for future research experiments unifying physical exercise and creative activities into tailored interventions designed to better comprehend this disease and perhaps counteract the devastating implications dementia prognoses present to optimal physical and mental functioning across the human life span.
Elsevier,

Reaching Net Zero, What It Takes to Solve the Global Climate Crisis, 2020, Pages 107-122

This book chapter advances SDG 11, 13, 17 by describing the Intergovernmental Panel on Climate Change and other reports on the need to limit global temperature increase to 2.0°C and preferably 1.5°C. The chapter outlines possible scenarios and introduces the concept of “net zero” by 2050, the essential elimination of greenhouse gas emissions. The chapter also discusses why this deadline is not achievable and presents a more likely scenario.
Elsevier,

Food Safety, Past, Present, and Predictions, 2020, Pages 179-203

This book chapter addresses SDGs 2 and 17 by explaining the past, present and future of food safety.
The health sector has an important role to play in terms of offering culturally appropriate and relevant care, tackling racism in the health care sector, improving engagement with Indigenous partners, and advocating for decolonizing policies that give control of health and wellness to the Indigenous people of Canada.
Elsevier,

Evidence-informed Approaches for Managing Dementia Transitions: Riding the Waves, Volume , 4 February 2020

This book chapter advances SDGs 3 and 17 by focusing on the need to establish equilibrium and well-being and is organized around eight themes using the acronym R-E-A-D-J-U-S-T. The chapter ties these themes with a call for more research and reinforcement for inclusion of the voices of people with dementia.
Elsevier,

Evidence-informed Approaches for Managing Dementia Transitions: Riding the Waves, Volume , 4 February 2020

This book chapter advances SDGs 3 and 17 by introducing aspects of the lived experience, management, and epidemiology of dementia and some of the significant transitions that people with the disease and their caregivers frequently encounter.
Elsevier,

Evidence-informed Approaches for Managing Dementia Transitions: Riding the Waves, Volume , 4 February 2020

This book chapter advances SDGs 3 and 17 by describing the prevalence of dementia in hospitalized patients, reasons for hospitalizations, and risks to older people with dementia in hospitals. Strategies for optimizing outcomes and models of care that are designed to improve care of persons with dementia and their care partners are described to assist healthcare team members working with this unique population.
This book chapter advances SDGs 3 and 17 by reviewing a new promising neuroprotective approach to treating AZ, Tau-based therapies including tau-kinase inhibitors to acetylation inhibitors, microtubule stabilizers, aggregation inhibitors, monoclonal anti-tau antibodies or active tau vaccines. Special emphasis has been placed on the most promising therapeutic agents that have reached clinical trials.

Pages